Literature DB >> 20880113

Lenalidomide-induced tumour flare reaction in mantle cell lymphoma.

Heather E Eve, Simon A J Rule.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20880113     DOI： 10.1111/j.1365-2141.2010.08376.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Authors:  Asher A Chanan-Khan; Kasyapa Chitta; Noreen Ersing; Aneel Paulus; Aisha Masood; Taimur Sher; Abhisek Swaika; Paul K Wallace; Terry L Mashtare; Greg Wilding; Kelvin Lee; Myron S Czuczman; Ivan Borrello; Naveen Bangia
Journal:  Br J Haematol       Date:  2011-10-20       Impact factor: 6.998

Review 2.  Rethinking clinical response and outcome assessment in a biologic age.

Authors:  Bruce D Cheson
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

3.  Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Authors:  Han W Tun; Patrick B Johnston; Lisa M DeAngelis; Pamela J Atherton; Levi D Pederson; Patricia A Koenig; Craig B Reeder; Antonio M Padula Omuro; David Schiff; Brian O'Neill; Jose Pulido; Kurt A Jaeckle; Christian Grommes; Thomas E Witzig
Journal:  Blood       Date:  2018-09-27       Impact factor: 22.113

4.  Tumor flare reaction in a patient with mantle cell lymphoma.

Authors:  Yusuf Kayar; Nuket Bayram Kayar
Journal:  Blood Res       Date:  2014-12-23

Review 5.  Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies.

Authors:  Susan Blumel; Jackie Broadway-Duren
Journal:  J Adv Pract Oncol       Date:  2014 Jul-Aug

6.  Tumour flare reaction in cancer treatments: a comprehensive literature review.

Authors:  Amina Taleb B
Journal:  Anticancer Drugs       Date:  2019-10       Impact factor: 2.248

7.  Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report.

Authors:  Chunting Zhu; Yi Zhao; Fang Yu; Weijia Huang; Wenjun Wu; Jingsong He; Zhen Cai; Donghua He
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

8.  Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.

Authors:  P L Zinzani; J M Vose; M S Czuczman; C B Reeder; C Haioun; J Polikoff; H Tilly; L Zhang; K Prandi; J Li; T E Witzig
Journal:  Ann Oncol       Date:  2013-09-12       Impact factor: 32.976
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.